Integrated Ventures Receives An Approval To Be Relisted On OTCQB Venture Market

Integrated Ventures Receives An Approval To Be Relisted On OTCQB Venture Market

PR Newswire

PHILADELPHIA, Oct. 12, 2017 /PRNewswire/ — Integrated Ventures, Inc. (OTC: INTVD) is pleased to announce that  the Company has regained a full compliance with OTCQB requirements and has been readmitted to the OTCQB Venture Market. 

Effective, October 12, 2017, the Company’s shares will be trading again on OTCQB under the symbol INTV with the fifth character “D”, which was added on September 21, 2017, for a period of 20 trading days to indicate that the Reverse Stock Split has occurred. The Company expects that its common stock will revert to the trading under its original symbol “INTV”, on October 20, 2017.

Steve Rubakh, CEO of Integrated Ventures, Inc, states: “We are extremely happy to be back on OTCQB and to be among other premier OTC companies. It must be noted that in order to be eligible for relisting on OTCQB,  the Company had to remain current in its financial reporting, to have a minimum bid price of $0.01 and to complete an annual verification and management certification process. Such fast approval for the relisting on OTCQB Venture Market, clearly indicates the Company’s commitment in the building the shareholder’s value and enabling the management team to rapidly move forward with execution of the new business plan. In addition, the Company plans to file its current 10Q ahead of schedule and is very confident that financial results will confirm and reinforce a positive momentum in terms of stock pricing.”

About Integrated Ventures, Inc:

The Company is focused on acquiring, launching and operating  companies, primarily in the crypto currency, blockchain  technology, mobile applications and healthcare transportation sectors.

For more details about Integrated Ventures, Inc, please visit

About Bitco Lab, Inc:

This wholly owned subsidiary is pursuing opportunities in the crypto currency sector with focus on bitcoin mining, hosting, pooling, manufacturing and distributing of own brand of mining equipment and the development of blockchain based applications for financial markets.

For more details about Bitco Lab, Inc, please visit 

Safe Harbor Statement: 

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, and various other factors beyond the Company’s control.

Steve Rubakh 
(215) 962-4558


View original content:

SOURCE Integrated Ventures, Inc.

Invesco Announces Reverse Share Split for the PowerShares WilderHill Clean Energy Portfolio (NYSE Arca: PBW)


Invesco Announces Reverse Share Split for the PowerShares WilderHill Clean Energy Portfolio (NYSE Arca: PBW)

PR Newswire

DOWNERS GROVE, Ill., Oct. 9, 2017 /PRNewswire/ – Invesco (NYSE: IVZ), a leading provider of exchange traded funds (ETFs), announced today a reverse share split for the PowerShares WilderHill Clean Energy Portfolio (PBW).

PowerShares by Invesco (PRNewsFoto/Invesco PowerShares Capital Mana)

Effective at the close of markets on Friday, October 20, 2017, the Fund will affect a 1-for-5 reverse split of its issued and outstanding shares.  Monday, October 23, 2017 is the first day of trading for the Fund on a split-adjusted basis.  The split does not change the total value of a shareholder’s investment.  While the ticker symbol of the Fund will not change, it will receive a new CUSIP number.  The Fund’s new CUSIP is 73935X112. 

Investors will receive one post-split share for every five pre-split shares owned.  As a result, post-split shares would be priced five times higher than the pre-split shares.

The table below illustrates a hypothetical 1-for-5 reverse split (actual net asset value, shares and market price may vary):

# of Shares Owned


Value of Shares









**For Illustrative Purposes Only

This reverse split does not impact fund performance, however, investors should be aware of the adjustment in shares outstanding and per share NAV when comparing historical values or their monthly brokerage statements.

For shareholders who own a number of shares that is not an exact multiple of the reverse split ratio (in the case of this reverse split, a multiple of five), the reverse split will result in the creation of fractional shares.  As fractional shares cannot trade on an exchange, these shares will be redeemed for cash.  With respect to the redemption of these fractional shares, this may cause a realization of gains or losses, which could be a taxable event for shareholders. 

About Invesco
Invesco is an independent investment management firm dedicated to delivering an investment experience that helps people get more out of life. NYSE: IVZ;

About PowerShares by Invesco
PowerShares by Invesco is leading the Intelligent ETF Revolution® through its family of more than 140 domestic and international PowerShares exchange-traded funds (ETFs). PowerShares ETFs seek to outperform traditional benchmark indexes while providing advisors and investors access to an innovative array of focused investment opportunities. PowerShares has US franchise assets exceeding $158 billion as of June 30, 2017. For more information, please visit us at or follow us on Twitter @PowerShares.

Important Risk Information

Shares are not FDIC insured, may lose value and have no bank guarantee.

There are risks involved with investing in ETFs, including possible loss of money. Shares are not actively managed and are subject to risks similar to those of stocks, including those regarding short selling and margin maintenance requirements. Ordinary brokerage commissions apply. The Fund is subject to certain other risks. Please see the current prospectus for more information regarding the risk associated with an investment in the Fund.

Investments focused in a particular industry, such as clean energy and semiconductors, are subject to greater risk, and are more greatly impacted by market volatility, than more diversified investments.

Stocks of small and mid-sized companies tend to be more vulnerable to adverse developments, may be more volatile, and may be illiquid or restricted as to resale.

Shares are not individually redeemable and owners of the Shares may acquire those Shares from the Fund and tender those Shares for redemption to the Fund in Creation Unit aggregations only, typically consisting of 10,000, 50,000, 75,000, 100,000 or 200,000 Shares.

Before investing, investors should carefully read the prospectus/summary prospectus and carefully consider the investment objectives, risks, charges and expenses. For this and more complete information about the Fund call 800 983 0903 or visit for the prospectus/summary prospectus.

View original content with multimedia:

SOURCE Invesco

Institutional Shareholder Services, Inc., Recommends CytRx Corporation Stockholders Vote “FOR” the Proposed Reverse Stock Split

Institutional Shareholder Services, Inc., Recommends CytRx Corporation Stockholders Vote “FOR” the Proposed Reverse Stock Split

PR Newswire

LOS ANGELES, Oct. 4, 2017 /PRNewswire/ – CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Institutional Shareholder Services, Inc. (ISS), the leading global independent proxy advisory firm, issued a report on September 28, 2017, recommending that CytRx stockholders vote “FOR” the proposed reverse stock split at the upcoming special meeting of stockholders scheduled for October 17, 2017 at 10:00 a.m. PT.

ISS is the most prominent independent proxy voting and corporate governance advisory firm, and its recommendations are relied upon by institutional investment firms, mutual funds and other fiduciaries globally.  ISS’ experienced research team provides comprehensive proxy analyses and complete vote recommendations for approximately 40,000 meetings annually in around 117 markets worldwide.

“The supportive recommendation by ISS adds to the prior positive recommendation by Glass Lewis & Co. to vote in favor of the reverse stock split proposal,” commented Dr. Louis Ignarro, Nobel Laureate and Lead Director of CytRx. “Both of these independent advisory firms recognize that maintaining CytRx’s listing on Nasdaq is of value to the Company and its stockholders.”   

ISS and Glass Lewis are independent proxy advisory firms and do not have any business relationship with CytRx.  CytRx did not engage or compensate either firm for their analysis or recommendations. 

CytRx stockholders are urged to vote as ISS and Glass Lewis recommend by voting “FOR” the proposed reverse stock split.  Stockholders with questions may call Saratoga Proxy Consulting LLC at (888) 368-0379 or (212) 257-1311 or by email at

How to Vote

If you are a stockholder of record at the close of business on August 28, 2017, you can vote your shares in one of two ways: either by proxy or in person at the special meeting. If you chose to submit a proxy, you may do so by telephone, via the internet or by mail. If you hold shares of CytRx common stock in multiple accounts, you should vote your shares as described in each set of proxy materials you receive. CytRx highly recommends stockholders vote electronically or by phone without delay. Please have your proxy card with you while voting.

You may transmit your proxy voting instructions via the Internet by accessing and following the instructions. You may also transmit your proxy voting instructions by calling the telephone number specified on the proxy card. If you chose to vote via the Internet or phone, you do not have to return the proxy card.

For stockholders who still need assistance voting their shares, or have questions regarding the special meeting, please contact CytRx’s proxy solicitation firm, Saratoga Proxy Consulting, either by telephone: (888) 368-0379 or (212) 257-1311 or by email:

This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed reverse stock split. STOCKHOLDERS ARE URGED TO READ CAREFULLY AND IN ITS ENTIRETY THE DEFINITIVE PROXY STATEMENT AND ANY AMENDMENTS FILED WITH THE SEC, AND OTHER RELEVANT MATERIALS, BECAUSE THEY DO AND WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY AND THE PROPOSED REVERSE STOCK SPLIT.  The amended definitive proxy statement was mailed to stockholders of record as of August 28, 2017.  Stockholders may obtain free copies of the Company’s definitive proxy statement, any amendments to the proxy statement and its other SEC filings electronically by accessing the SEC’s home page at  Copies can also be obtained, free of charge, upon written request to CytRx Corporation, Attn: Corporate Secretary, 11726 San Vicente Blvd., Suite 650, Los Angeles, CA 90049.

Participation in Solicitation

This press release may constitute soliciting material under SEC Rule 14a-12, and CytRx and its directors, executive officers, and advisors may be deemed to be participants in the solicitation of proxies from the holders of CytRx common stock in respect of the proposed reverse stock split.  Investors may obtain additional information regarding the interest of those participants by reading the Company’s definitive proxy statement, any amendments to the definitive proxy statement and other relevant proxy materials, and the Company’s annual reports on Form 10-K and quarterly reports on Form 10-Q, as filed with the SEC.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical company specializing in research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. Aldoxorubicin, CytRx’s most advanced drug conjugate, is an improved version of the widely used chemotherapeutic agent doxorubicin and has been out-licensed to NantCell, Inc.  CytRx is also rapidly expanding its pipeline of ultra-high potency oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx’s expertise in albumin biology and linker technology for the development of a new class of potential breakthrough anti-cancer therapies.

Forward-Looking Statements

This press release contains forward-looking statements. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks and uncertainties relating to plans for regaining compliance with the NASDAQ rules and higher share price of our common stock; the ability of NantCell, Inc., to obtain regulatory approval for its products that use aldoxorubicin; the ability of NantCell, Inc., to manufacture and commercialize products or therapies that use aldoxorubicin; the amount, if any, of future milestone and royalty payments that we may receive from NantCell, Inc.; our ability to develop new ultra-high potency drug candidates based on our LADRTM technology platform; and other risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date of CytRx’s most recent annual report. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact: 
Argot Partners 
Michelle Carroll 
(212) 600-1902


View original content:

SOURCE CytRx Corporation